Abstract
Since the SARS-CoV-2 infection was identified in December 2019, SARS-CoV-2 infection has rapidly spread worldwide and has become a significant pandemic disease. In addition, human death and serious health problem caused by SARS-CoV-2 infection, the socio-economic impact has been very serious. Here, we describe the development of the viral vector vaccine, which is the receptor-binding domain (RBD) of SARS-CoV-2 expressed on the surface of Newcastle disease virus (LVP-K1-RBD19). The RBD protein concentrations on the viral surface were measured by the sandwich ELISA method. 106.7 TCID50/ml of LVP-K1-RBD19 has a 0.17 μg of RBD protein. Optical density (OD) values of mouse sera inoculated with 10 μg of RBD protein expressed on the surface of LVP-K1-RBD19 generated 1.78-fold higher RBD-specific antibody titers than mice inoculated with 10 μg RBD protein with alum at 28 dpi. Moreover, mice inoculated with 10 μg of RBD protein expressed on the surface of LVP-K1-RBD19 virus showed more than 80% neutralization at 1:256 against the SARS-CoV-2 pseudovirus. These results demonstrated that inactivated LVP-K1-RBD19 virus produces neutralizing antibodies against SARS-CoV-2 in a short period and could be elect protective immunity in humans and LVP-K1-RBD19 will be a good candidate for the COVID-19 vaccine.
Highlights
Pneumonia like severe respiratory symptom patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) was first reported in Wuhan, Hunan province, China in December 2019 [1,2,3]
We describe the development of the viral vector vaccine, which is the receptor-binding domain (RBD) of SARS-CoV-2 expressed on the surface of Newcastle disease virus (LVP-K1-RBD19)
Optical density (OD) values of mouse sera inoculated with 10 μg of RBD protein expressed on the surface of LVP-K1-RBD19 generated 1.78-fold higher RBD-specific antibody titers than mice inoculated with 10 μg RBD protein with alum at 28 dpi
Summary
Pneumonia like severe respiratory symptom patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) was first reported in Wuhan, Hunan province, China in December 2019 [1,2,3]. February 1, 2020, 11,821 patients having severe pneumonia as symptoms reported in China and 132. The RBD of SARS-CoV-2 express on the viral surface of the NDV as a viral vector vaccine candidate patients confirmed by new emerging virus and this virus infection reported in 23 countries including China [6]. More than one hundred million people are infected per day and more than two million people were died by virus infection. The virus is transmitted to 221 countries every day 250,000 through 500,000 people are infected every day and 10,000 people have died. Since 1918 Spanish flu, SARS-CoV-2 as a pandemic disease affect most seriously affect human health and the economy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
